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 Introduction 
 Liver diseases represent an increasing health burden 
and an enormous human and financial cost to the com-
munity, and liver transplantation is currently the only 
long-term therapeutic option for patients with end-stage 
liver disease. While immunosuppressive medication pre-
vents allograft rejection by suppressing the patient’s im-
mune responses toward the donor liver, these drugs place 
the recipient at risk of cardiovascular disease, malignan-
cy and infection. Clinicians strive to minimize immuno-
suppressive medication without increasing the risk of re-
jection. Ultimately, the goal is to achieve transplantation 
tolerance, a state whereby the recipient, in the absence of 
immunosuppression, does not mount an immune re-
sponse against the donor organ, while maintaining the 
capacity to respond to pathogens and tumors.
 Liver transplants are unique compared to other solid 
organ grafts: they are spontaneously accepted in a wide 
range of animal models, including across completely 
MHC-mismatched mouse and rat inbred strain combi-
nations  [1] . Liver transplants can also reverse ongoing 
rejection of previous organ allografts from the same do-
nor strain, including heart  [2] , pancreas  [3] and skin  [4, 
5] .
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 Abstract 
 Unlike other solid organs, liver transplants are spontaneous-
ly accepted in a wide range of animal models. In the clinic, 
transplanted livers also display privileged immunological 
properties allowing weaning of immunosuppression thera-
py in up to 20% of selected patients. To explain this phenom-
enon, many studies have focused on the role of donor-de-
rived ‘passenger’ leukocytes that are thought to induce an-
tigen-specific tolerance by migrating from the graft into 
recipient secondary lymphoid tissues. Although convincing 
evidence exists that these cells are able to elicit antiallograft 
T cell hyporesponsiveness, several studies argue against an 
exclusive role for this cell population and even question 
whether it is critical in conferring donor MHC-specific toler-
ance. Instead, these studies suggest that the hepatic paren-
chyma plays a more critical role in this phenomenon. In this 
review we will reinterpret the results of old and more recent 
literature in light of recent advances in the field of liver im-
munology to explain the contribution of both passenger leu-
kocytes and liver tissue in the liver tolerance effect. 
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 Human liver transplants require less immunosuppres-
sion than other organs  [6] and, unlike renal transplants, 
early rejection episodes do not affect long-term graft sur-
vival  [7] . In about 20% of selected liver recipients, immu-
nosuppression can even be weaned off completely with-
out rejection of the allograft  [8–10] , although specific bio-
markers to identify such patients are still lacking  [11] .
 Various models have been proposed to explain liver 
transplant tolerance. Most studies in rats have highlight-
ed both the role of donor passenger leukocytes and the 
liver tissue in this process, but their relative contribution 
and mechanisms are still unknown. Passenger leuko-
cytes migrate to secondary lymphoid tissues where they 
are thought to induce an ‘abnormal’ activation of graft-
reactive T cells, leading to tolerance  [12, 13] . The mecha-
nisms by which the liver tissue induces tolerance are even 
more enigmatic. In this review, we will reinterpret old 
and recent findings to explain how the liver tissue con-
tributes to the spontaneous acceptance of liver allografts.
 Liver Transplantation Is Associated with the 
Induction of Tolerance 
 In 1969, Sir Roy Calne  [14, 15] reported for the first 
time that liver transplants were accepted in outbred pigs 
in the absence of immunosuppressive drugs, opening a 
new area of research in transplantation immunology. Liv-
er acceptance between outbred individuals has been con-
firmed in several other species  [5, 16–19] . Using inbred 
mouse and rat strains, it was confirmed that liver trans-
plants were accepted between several complete MHC 
mismatch barrier combinations  [5, 16–18] . In contrast, 
kidneys were rejected at day 12  [20] , while hearts under-
went rejection after 8 days  [21] . Likewise, in clinical prac-
tice, unlike renal transplants, HLA-matching of liver 
transplant recipients and donors is not necessary  [22–25] .
 A decade after the pioneering observation by Calne, 
Kamada and colleagues were able to demonstrate, in rats, 
that recipients of liver grafts also accepted subsequent 
skin or heart transplants from the same donor strain 
while rejecting third-party grafts  [5, 16–18] . Liver trans-
plants were also able to reverse severe ongoing rejection 
of previous organ transplants from the same strain, in-
cluding heart  [2] , pancreas  [3] and skin  [4, 5, 17] . Liver 
transplants could reverse ongoing rejection even 6 days 
after transplantation of the heart, but only in 50% of cas-
es, while both organs were rejected when the liver was 
transplanted after 6 days  [26] , indicating that there was 
an ‘all-or-nothing’ threshold between rejection and ac-
ceptance. These findings are consistent with the clinical 
observation that the combined transplantation of a liver 
with another organ from the same donor results in fewer 
rejection episodes of the organ, including kidney  [27] , 
heart  [28] , lung and multiorgan recipients  [29] . These ex-
periments reinforced the view that liver grafts were not 
ignored by the immune system, but rather induced anti-
gen-specific tolerance.
 Histology of Tolerant and Rejecting Liver Grafts 
 Several studies have followed to dissect mechanisms of 
tolerance associated with spontaneous liver transplant 
acceptance. In mice, the surgery is extremely difficult. 
For this reason, most studies have been performed in rats 
in which both tolerant and rejecting strain combinations 
have been reported. PVG rat strain livers transplanted
to completely MHC-mismatched DA-strain recipients 
(PVG ] DA) did not reject the liver for more than 100 
days, even though they received no immunosuppression 
 [18, 30] . In contrast, PVG ] Lewis liver allografts were 
rapidly rejected  [18] . Spontaneous acceptance of the PVG 
liver into the DA recipient was associated with hypore-
sponsiveness of the recipient to another graft from the 
same donor while rejecting a third-party organ at a nor-
mal pace, suggesting that it had induced donor-specific 
tolerance. Many groups have used these strain combina-
tions to determine whether there are differences between 
tolerant and rejecting combinations.
 The presence of cellular infiltrates and focal necrosis 
of hepatocytes in tolerant liver grafts during the first 2 
weeks confirmed that tolerant liver transplants were not 
ignored by the recipient’s immune system, but instead 
tolerance was associated with vigorous activation of  the 
adaptive immunity  [26] . Interestingly, experiments in the 
rat allograft model indicated that allograft damage oc-
curred early in the post-transplant period, irrespective of 
whether the allograft was rejected or accepted  [26] , rais-
ing the question of how immune activation and allograft 
damage could alter the final outcome. By comparing the 
composition of infiltrates in the liver graft of accepting 
and rejecting strain combinations, Sun et al.  [31] showed 
that there were minor differences in the proportion of 
CD11b+ (macrophages) and CD3+ cells (T cells). How-
ever, the liver of tolerant recipients contained a higher 
proportion of IgD+ cells (B cells). The significance of this 
difference was not clear. Other studies have confirmed 
that there is little difference in liver T cell infiltrates be-
tween rejecting and accepting strain combinations  [32] .
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
, R
eg
en
sb
ur
g
13
2.
19
9.
14
5.
19
5 
- 1
0/
24
/2
01
9 
3:
34
:0
2 
PM
 Hepatic Parenchyma and Liver 
Transplant Tolerance 
Dig Dis 2011;29:391–401 393
 Cellular infiltration in liver grafts has often been as-
sociated with apoptosis of both hepatocytes and infil-
trating leukocytes in animal models, but also in clinical 
liver transplantation  [33–35] . Interestingly, apoptosis of 
lymphocytes also occurred in parallel in lymphoid tis-
sues  [36, 37] , suggesting that recipient T cells might be-
came apoptotic as a result of their activation. In acute 
rejection, the level of apoptosis within the graft corre-
lated with the severity of the rejection  [33, 35] , and reduc-
ing apoptosis by knocking down IL-2 prevented rejection 
in the LEW to BN rat strain combination  [38] . On the 
other hand, apoptosis was also observed in liver trans-
plants that were accepted, and in the study by Qian et al. 
 [39] , reducing apoptosis in the liver by IL-2 treatment 
converted liver transplant tolerance to rejection  [39, 40] . 
To date, no definitive study has been performed to deter-
mine if it is apoptosis of the liver tissue, apoptosis of liv-
er infiltrates or apoptosis of leukocytes in secondary 
lymphoid organs that best correlates with liver trans-
plant tolerance.
 Role of Donor-Derived Leukocytes in Liver 
Transplantation Tolerance 
 Passenger Leukocytes and Microchimerism 
 The liver contains both resident leukocytes (e.g. Kupf-
fer cells) and leukocytes that are able to recirculate to 
lymphoid tissues following liver transplantation [also 
known as passenger leukocytes (PLs)]. By migrating to 
lymphoid tissues, PLs are thought to induce abortive ac-
tivation of recipient leukocytes leading to tolerance  [41] . 
It was proposed that the liver would be more prone to in-
duce tolerance than other solid organs due to its larger 
size  [42] and/or because it harbors a higher number of 
migratory donor PLs  [41] . Consistent with this proposal, 
several organs from the same donor transplanted at the 
same time survived longer than single organ transplants 
in both small animals  [42] as well as in humans  [43–45] . 
The mechanisms and exact contribution of this particu-
lar process to the spontaneous acceptance of liver grafts 
and liver tolerance ‘effect’ remain unclear. Depletion of 
donor PLs induced rejection  [46–48] , while the reconsti-
tution of donor PLs either through i.v. infusion  [42, 47] or 
parking the liver in a donor strain animal  [46] was able 
to restore tolerance. These experiments led some investi-
gators to suggest that this is the major pathway by which 
liver PLs induced tolerance. 
 This view was consolidated when, in 1992, Starzl et al. 
[49] demonstrated that liver transplant patients com-
pletely weaned off all immunosuppression drugs dis-
played long-term donor cell chimerism. The model of 
‘microchimerism’, which describes the existence of a very 
low ( ! 1%) frequency of hematopoietic donor cells within 
the recipients blood and tissue, was born. According to 
this model, the outcome of liver transplants is determined 
by a limited graft-versus-host and host-versus-graft re-
sponse  [50] . These ‘two-way mixed lymphocyte reaction’ 
would reach a balance after several months during which 
immunosuppressive treatment could be decreased and 
eventually completely stopped  [51] . However, microchi-
merism alone could not explain spontaneous acceptance 
of liver grafts, as the existence of microchimerism failed 
to identify patients suitable for successful weaning of im-
munosuppressive therapy  [52, 53] . Instead, it has been 
postulated that microchimerism could represent a conse-
quence of tolerance rather than its cause  [54] .
 Evidence supporting a role for donor PLs has also been 
provided in a rat liver transplant model, where the donor 
liver was retransplanted into a recipient after being 
‘parked’ in another recipient of the same strain for sev-
eral weeks. The livers which were composed of donor-
derived parenchymal and liver-restricted leukocytes and 
recipient-derived PLs, were rejected following retrans-
plantation  [55] . Similar results were obtained by deple-
tion of donor leukocytes within the graft using irradia-
tion  [48] , while reconstitution of an irradiated liver by 
‘parking’ it in a recipient rat of the donor strain for 36 h 
before transplanting into an allogeneic host could restore 
tolerance  [46, 56] . In this context, it is important to note 
that irradiation might do more than depleting leuko-
cytes. For example, irradiation induces some inflamma-
tion and upregulation of adhesion molecules  [57] . In ad-
dition, NKG2D ligands MICA/B and ULBP1–3 proteins 
have been described as being upregulated following in-
flammation  [58] . These changes might alter the immune 
response independently of PLs.
 Use of Donor Splenocytes to Mimic the Role of PLs 
 Microchimerism and its mechanisms are still debated 
 [1] , but this model has inspired several investigators to 
examine the role of PLs in inducing antigen-specific T 
cell tolerance in a transplant setting. Infusion of donor 
leukocytes at the time of transplantation (to mimic PLs 
migrating out of the graft) has been used in several mouse 
and rat transplant models to prolong graft survival  [59, 
60] . These studies recapitulate the ability of donor PBMC 
to induce tolerance (the so-called ‘blood transfusion ef-
fect’  [61] ) and have demonstrated some (sometimes lim-
ited) success in extending graft survival. This was highly 
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dependent on the nature of the transplanted organ, the 
species and the number of PLs adoptively transferred. In 
rats, donor-derived splenocytes administered just before 
liver transplantation induced donor-specific tolerance 
 [42, 47] and led to acceptance of liver allografts that were 
normally rejected  [62] . Administration of donor spleno-
cytes was also able to induce tolerance to rat kidney al-
lografts  [62] . However, administration of donor spleno-
cytes was unable to convert skin allograft rejection into 
acceptance  [42] , nor heart allograft rejection into toler-
ance  [59] . In most cases, donor leukocytes alone were not 
able to induce long-term acceptance of allogeneic trans-
plants. This could only be achieved when the recipients 
also received other treatments either pharmacologically 
(e.g. calcineurin-inhibitors)  [59, 63] or by blocking co-
stimulatory molecules, signal 2 in T cell activation, using 
antibodies (e.g. CD154 mAb)  [64] .
 The nature of the donor splenocytes contributing to 
inducing tolerance or prolongation of graft survival has 
been reviewed elsewhere and is not the focus of this re-
view  [1] . In summary, although T cells  [42, 55] , B cells  [65, 
66] and dendritic cells (DCs)  [67] have been shown to play 
some role in inducing tolerance, the nature of the cellular 
subset, and whether the spleen and lymph nodes play a 
similar role in activating and/or deleting alloreactive T 
cells remains unsolved. Although they are able to induce 
tolerance, it is also not clear whether the injection of do-
nor splenocytes into transplant recipients is representa-
tive of the migration of liver PLs after transplantation.
 Intrahepatic Leukocytes 
 The liver harbors different subsets of lymphocytes that 
differ from those of the blood and spleen, including he-
matopoietic stem cells, unique subsets of DCs  [67, 68] , 
and a high proportion of natural killer (NK) and natural 
killer T (NKT) cells  [69] . It is thus possible that it is the 
qualities of liver leukocytes, rather than the quantity, that 
induces tolerance.
 Role of Liver DCs  
 The total number of DCs in a normal liver is up to five-
fold  [70] higher than in other solid organs, but the volume 
density is the lowest of all organs  [70] . Most studies agree 
that freshly isolated hepatic DCs are immature and are 
less immunogenic than splenic DCs  [71, 72] . They express 
low levels of MHC class II and costimulatory molecules 
(CD80 and CD86), a finding consistent with their poor 
allostimulatory ability in MLR assays  [73, 74] . They also 
secrete IL-10  [75] and display a higher threshold for acti-
vation than splenic DCs due to decreased expression of 
Toll-like receptor 4  [76] . It has been proposed that hepat-
ic DCs induce apoptosis, possess immune regulatory/
suppressive functions  [77] and might participate in the 
generation of regulatory T cell (T reg ) populations  [78, 79] . 
However, their immature phenotype and location in the 
portal tracts argue against their role in inducing sponta-
neous acceptance of liver transplants. Consistent with 
limited DC contribution in the liver tolerance effect, ad-
ministration of the Flt3 ligand, which increases the num-
ber of DCs, caused rejection of liver allografts  [80] . In 
humans, BDCA-1+ DCs were the most prevalent DC sub-
set in the liver in contrast to CD16+ DCs in the blood. In 
direct comparison, between human liver and blood, DCs 
produced large amounts of IL-10 and induced FoxP3-
positive T reg and IL-4 producing Th2 cells, while being 
less effective in inducing proliferation of allogenic T cells 
 [81] .
 Although the role of hepatic DCs in inducing sponta-
neous tolerance to liver allografts remains speculative, 
manipulation of DCs has the potential to be used as a 
therapy. Several investigators have shown that human 
and mouse DC manipulated ex vivo with cytokines such 
as IL-10  [82] , TGF-   [83] and TNF-   [56] , or pharmaco-
logical reagents like dexamethasone or mitomycin C  [84] 
were able to promote antigen-specific hyporesponsive-
ness.
 In addition to DCs, the liver contains sufficient hema-
topoietic stem cells to reconstitute lethally irradiated re-
cipients  [85, 86] . These cells have been suggested to play 
some role in tolerance by migrating into the recipient thy-
mus and inducing negative selection of donor-derived T 
cells  [87, 88] . Although this might occur and be impor-
tant for the long-term maintenance of tolerance and the 
establishment of microchimerism, it is unlikely that it 
contributes significantly to establish tolerance, as thy-
mectomy does not interfere with liver transplant toler-
ance  [41, 89] .
 Role of NK/NKT Cells  
 NK and CD8+ CD69+ lymphocytes expressing high 
levels of MHC class II and CD25 are detected in portal 
tracts and perisinusoidal areas of liver transplants  [90] , 
indicating that they might play some role in inducing tol-
erance by interacting with resident recipient leukocytes 
 [91] .
 Some in vitro experiments indicate that both NK and 
NKT cells display some indirect tolerogenic properties 
that require the presence of hepatocytes. NK cell interac-
tion with hepatocytes in vitro led to NKG2A-dependent 
secretion of TGF-  , generating tolerogenic DCs which in 
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turn induced CD4+ CD25+ T reg  [92] . Likewise, hepato-
cytes induced NKT cells to secrete IFN-  and tolerogen-
ic CD8+ T cells secreting IL-10  [93] .
 In vivo studies suggest, however, that NK/NKT cells 
are more involved in rejection than in protecting the 
graft. Administration of an antibody that depleted al-
most all NK and NKT cells prior to transplantation of a 
fully MHC-mismatched DA liver transplant into a Lewis 
recipient rat prolonged allograft survival from 10 to 19 
days, while depletion of host CD8+ T cells did not prevent 
liver allograft rejection  [94] . It is interesting to note that 
in this model, all intrahepatic NK cells were of host origin 
as soon as day 3 after transplantation, indicating that at 
least in this model, rejection was mediated by host NK 
and/or NKT cells rather than donor NK/NKT cells. How-
ever, a recent study showed, by depleting donor NK cells 
before transplant, that donor liver NK cells were not vi-
tally important for induction of liver transplant tolerance 
in the PVG to DA rat strain combination  [95] . Other stud-
ies support a role of NK cells in inducing rejection  [96] , 
and in the clinic matching HLA-C (a major inhibitory 
ligand for NK cells) has also been associated with a better 
long-term survival of liver transplants  [97] , thus support-
ing the hypothesis that NK/NKT cells can induce rejec-
tion.
 Role of the Hepatic Parenchyma in Liver Transplant 
Tolerance 
 The concept that donor PLs play the most critical role 
in spontaneous liver transplant acceptance has been rela-
tively popular due to the attractive model of microchime-
rism and experiments using adoptively transferred donor 
leukocytes. However, this mechanism alone is not suffi-
cient to explain why liver grafts are accepted spontane-
ously. As mentioned before, microchimerism is not al-
ways associated with graft survival. Furthermore, donor 
splenocyte administration only prolongs the survival of 
kidney allografts, but has no effect on the survival of oth-
er organs (such as skin and heart)  [42, 55] .
 Evidence for a Role of the Liver Tissue in Spontaneous 
Acceptance of Liver Grafts 
 Experiments performed by Calne and colleagues  [56] 
have also emphasized the secondary role of PLs. In these 
experiments, the donor graft was a chimeric liver in 
which the migratory PLs were the only cells expressing 
the alloantigen. This liver was obtained by performing 
two successive transplants: a PVG strain liver was trans-
planted into a DA recipient and 20 days later, when the 
PVG liver was repopulated with DA leukocytes, the liver 
was retransplanted into a secondary PVG recipient. Al-
though now containing passenger DA leucocytes, the 
chimeric transplanted liver grafts completely failed to 
prolong the survival of subsequent DA skin grafts, sug-
gesting that PLs alone were unable to induce tolerance. 
To examine the role of the nonmigratory cells (liver tis-
sue including hepatocytes, liver sinusoidal endothelial 
cells, Kupffer cells and stellate cells) in this process, the 
same investigators generated the reverse transplant chi-
mera, in which a DA liver reconstituted with passenger 
PVG leukocytes into a PVG rat. In contrast to the other 
chimeras in which activation was induced by PLs, the 
survival of DA skin grafts on these chimeric transplant 
recipients was prolonged in the absence of DA PLs, sug-
gesting that parenchymal cells were able to induce toler-
ance. 
 Chiba et al.  [55] also confirmed the important role of 
the liver tissue by reporting a very intriguing finding. 
They repeated the experiments performed by Sun et al. 
 [42, 46] showing that irradiation of a DA liver before 
transplantation into a PVG host, 24 h later, abrogated the 
spontaneous acceptance normally observed in this com-
bination. They confirmed that if they reconstituted the 
donor just after irradiation with DA splenocytes, they 
could restore spontaneous acceptance of the liver graft. 
The surprising result was that if they reconstituted the 
donor with third-party (BN) splenocytes expressing a 
different allo-MHC molecule, acceptance was also re-
stored. Recipient rats accepting the DA liver graft and 
injected with DA or BN splenocytes rejected a BN heart, 
but did not reject a DA heart, indicating that splenocytes 
restored tolerance regardless of their MHC haplotype 
and that the specificity of the tolerance depended on the 
MHC of the liver tissue rather than on that of splenocytes 
 [55] . By injecting purified T and B cells instead of spleno-
cytes, the authors of this study showed that restoration of 
the tolerance effect was conferred by T cells and suggest-
ed that T cells secreting immunomodulatory cytokines 
(potentially T reg ) were involved. 
 These results point out the critical role played by pa-
renchymal cells and the liver tissue in spontaneous ac-
ceptance of liver allografts. Similar results were obtained 
by Kreisel et al.  [98] by creating bone marrow chimeric 
rats: third-party bone marrow was as effective as the bone 
marrow of donor origin in inducing acceptance of the 
liver transplant. Again, in these experiments, the liver tis-
sue was important in conferring the MHC specificity 
 [98] , arguing against a critical role for PLs in inducing 
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donor-specific tolerance. Similar results were obtained 
using chimeric mouse models  [99] .
 In summary, there is substantial data in the literature 
to suggest that the non-bone marrow-derived component 
of the liver graft (including hepatocytes, liver sinusoidal 
endothelial cells and potentially stellate cells) play a crit-
ical role in inducing donor-specific tolerance. Two non-
exclusive models could explain the role of MHC-restric-
tion in this tolerance: soluble MHC molecules and direct 
T cell activation by liver cells.
 The Role of Liver Tissue in Secreting Soluble MHC 
Molecules 
 The liver secretes soluble MHC class I molecules, and 
following transplantation, high amounts of these mole-
cules are found in the serum  [17, 100] . This has led some 
investigators to speculate that soluble MHC molecules 
might play a role in inducing spontaneous acceptance of 
liver transplants and be responsible for the effect of the 
liver tissue (in particular hepatocytes) in this phenome-
non. Transplantation of livers from MHC class I-deficient 
donors did not prevent acceptance of the liver  [101] , but 
these studies are hard to interpret as allogeneic T cells 
would also ignore MHC class I-deficient liver. 
 Studies in which recipients were administered soluble 
MHC molecules are more convincing. Initial studies 
were disappointing and demonstrated that large quanti-
ties of soluble RT1a class I molecule from the DA strain, 
given intravenously to PVG recipients of DA cardiac al-
lografts by a variety of protocols, did not have any effect 
on graft survival  [102] . Similar results were obtained by 
other investigators  [103, 104] . Soluble MHC molecules 
were only effective in prolonging graft survival in com-
bination with cyclosporine treatment  [103] . However, 
these experiments were performed using a single soluble 
MHC molecule in a complete mismatch combination. 
 Using a single mismatch MHC molecule combination, 
Sumimoto and Kamada  [105] reported that the daily in-
jection of a DA rat serum (MHC haplotype RT1a) into a 
PVG (RT1c) rat receiving a heterotopic PVG (RT1a) do-
nor heart allograft prolonged the survival of the graft. 
Removal of the soluble MHC class I molecules by affinity 
chromatography abolished the immunosuppressive ef-
fect, indicating that MHC molecules were responsible for 
this result. Moreover, continuous infusion of purified sol-
uble class I antigen from DA rat liver, even from day 4 
after heart grafting, induced a significant prolongation of 
graft survival in a donor-specific manner. A mixture of 
monoclonal anti-class I (RT1a) antibody with DA serum 
by continuous infusion amplified the immunosuppres-
sive effect  [105] . Wang et al.  [106] also reported that 
RT1Aa heavy chain proteins injected into the thymus or 
into the portal vein 14 days before transplantation in-
duced indefinite survival of ACI liver allografts in Lewis 
(RT1l) recipients, but only when they were coadminis-
tered with anti-T cell receptor mAb  [106] . Further exper-
iments have confirmed the immunosuppressive effect of 
soluble MHC molecules. Geissler et al.  [107] transfected 
primary cultured Lewis hepatocytes so that they ex-
pressed either soluble or membrane-bound MHC class I 
molecules. By transplanting an ACI (RT1Aa) liver into a 
Lewis (RT1l) recipient, they demonstrated that hepato-
cytes secreting RT1Aa molecules injected into the portal 
vein extended liver allograft survival and decreased CTL 
activity. Interestingly, in contrast, recipients injected 
with hepatocytes expressing membrane-bound RT1Aa 
demonstrated accelerated graft rejection and primed 
CTLs  [107] .
 The mechanism by which soluble MHC molecules 
delay graft rejection is still a matter of debate, but it is 
thought that they play an important role at the very ear-
ly stages after transplantation by preventing hyperacute 
graft rejection induced by alloreactive antibodies  [108] . 
Soluble MHC would neutralize these antibodies, hence 
reducing organ damage and prolonging graft survival. 
A role for soluble MHC molecules in promoting apopto-
sis of alloreactive cytotoxic T cells  [109] has also been 
reported. Alternatively, it has been hypothesized that 
immature host DCs take up peptides derived from do-
nor soluble MHC molecules and present them to recipi-
ent T cells, leading to tolerance  [110, 111] . Consistent 
with this hypothesis, soluble donor MHC bound to a 
monoclonal antibody (so that it would be picked up by 
macrophages and DCs) was more effective in prolonging 
allograft survival than infusion of soluble donor MHC 
alone  [105] . However, there are also reports demonstrat-
ing that this indirect pathway of antigen presentation 
failed to induce tolerance to subsequent skin transplants 
 [112] .
 Collectively, these experiments suggest that adminis-
tration of soluble MHC class I alone has a minimal effect 
on graft survival by delaying rejection by a few days and, 
thus, cannot completely account for the role of the paren-
chyma to induce tolerance. In addition, human studies 
have shown no correlation between the large quantity of 
donor HLA in the sera, graft function  [113] or a state of 
tolerance  [114] . On the contrary, increased levels of solu-
ble MHC class I has been reported in the setting of rejec-
tion or infection  [115] .
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 The Role of the Liver Tissue in Inducing Abortive 
Primary T Cell Activation 
 Homing and entry of naïve and activated T cells into 
lymphoid tissues and organs including the liver are deter-
mined by complex molecular interactions involving ad-
hesion molecules that recognize their ligands on endo-
thelial cells  [116, 117] . Naïve T lymphocytes do not nor-
mally have access to the parenchyma of most organs, as 
they do not express adhesion molecules and chemokine 
receptors required for adhesion to endothelial cells or 
subsequent transendothelial migration  [116, 117] . How-
ever, naïve T cells express L-selectin (CD62L) which binds 
to peripheral LN-specific vascular addressins and has 
been shown to play a critical role in initial binding (teth-
ering) and subsequent rolling of the lymphocytes through 
the high endothelial venules of the LNs under normal 
conditions of flow  [118] . Chemokines and intercellular 
adhesion molecule-1/leukocyte function-associated anti-
gen-1 interactions also play an important role in these 
adhesion steps  [118] . In the LNs, naïve T cells interact 
with professional APCs, in particular DCs, expressing 
relevant peptide/MHC complexes. This contact induces 
T cell activation resulting in expression and upregulation 
of adhesion molecules, which allows activated T cells to 
undergo transendothelial migration and to infiltrate the 
tissues.
 T cells can enter the liver via the sinusoidal endothe-
lium  [119] . Sinusoids are formed by monolayers of hepa-
tocytes defining narrow channels approximately 10   m 
in diameter that are lined by a layer of specialized endo-
thelial cells and liver resident Kupffer cells  [120] . Unlike 
other endothelial cells, liver sinusoidal endothelial cells 
are perforated by multiple 120-nm diameter holes (fen-
estrations), and do not form tight junctions with adjacent 
endothelial cells  [121] . Entry via liver sinusoids is unique 
as it does not require selectins  [122, 123] . Lack of selectin 
requirement is thought to be due to a slower or intermit-
tent blood flow that favors intimate contact between leu-
cocytes and liver cells  [121] . These unique conditions of 
slow blood flow, in combination with the narrow diam-
eter of the hepatic sinusoids and their unusual structure 
favors contact between lymphocytes and liver cells re-
sulting in their retention. Early studies have established 
that while in the absence of their cognate antigen, naïve 
T cells recirculate through the liver without being re-
tained  [124–127] , and activated CD8+  [124, 126–128] 
and CD4+ T cells  [125] are very efficiently retained in a 
nonantigen-specific manner, even in the absence of in-
trahepatically expressed cognate antigen.
 We have suggested that the ability of the liver to induce 
tolerance is associated with its unique capability to retain 
and activate naïve alloreactive or antigen-specific CD8+ 
T cells  [123, 126, 127, 129] . In transplantation, such acti-
vation is likely to be mediated by donor liver sinusoidal 
endothelial cells and Kupffer cells that directly line the 
sinusoidal lumen  [71] and are able to directly contact re-
cipient T cells. Hepatocytes that are located underneath 
the physical barrier formed by liver sinusoidal endothe-
lial cells could be less accessible, although we have dem-
onstrated that hepatocyte/T cell contacts nevertheless oc-
cur via liver sinusoidal endothelial cell fenestrations 
 [120] . Retention and activation of antigen-specific naïve 
CD8+ T cells has been shown in the livers of transgenic 
mice specifically expressing the cognate antigen in hepa-
tocytes, in the absence of antigen expression in lymphoid 
tissues. Transgenic T cells were specifically retained in 
the livers of recipient mice within minutes and became 
activated within 2 h  [126] , suggesting that the liver is an 
exception to the general rule of T cell activation and re-
circulation, which predicts that naïve T cells recirculate 
via the lymph and blood, but do not enter peripheral tis-
sues prior to activation in secondary lymphoid organs. 
Antigen-presentation by hepatocytes to naïve CD8+ T 
cells was insufficient to promote activation and prolifera-
tion of the T cells, which subsequently died by death-by-
neglect in a Bim-dependent pathway in vitro and in vivo 
 [130, 131] . We predict that if this retention occurred in 
transplantation, it would result in the selective depletion 
of alloreactive T cells, leading to deletional tolerance. 
 Due to the difficulty of tracking very rare alloreactive 
T cells amongst the T cell repertoire, there has been no 
study reported to date investigating the retention of al-
loreactive T cells within hours after transplantation. 
However, some of the data in the literature is consistent 
with a model in which alloreactive T cells die by neglect. 
Treatment of rat liver transplant recipients with IL-2, a 
treatment that overcomes death-by-neglect induced by 
hepatocyte activation in vitro  [130, 131] and which is able 
to rescue anergic T cells, was able to induce rejection of 
liver grafts  [48] .
 Conclusion 
 Although there is convincing evidence that donor PLs 
play an important role in the liver tolerance effect, there 
is also evidence suggesting that the liver tissue itself plays 
a pivotal role in the antigen-specificity of this phenome-
non. It appears that both components, PLs and the paren-
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chyma, are needed to achieve a state of hyporesponsive-
ness, as neither the liver parenchyma alone nor donor leu-
kocytes could induce antigen-specific tolerance in robust 
rodent models. In addition, pre-existing factors like pre-
formed antibodies, prolonged ischemia times or cross-
reacting memory T cells might complicate the dissection 
of liver transplant tolerance in humans and explain why 
conclusions from small animals are often hard to trans-
late into the clinic.
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